⌕
Arcus Biosciences · RCUS · NYSE
Tenet 31 · Weak
Compare
$16.39−2.79%At closeTenet 31 · Weak
$16.39−0.47 (−2.79%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD

Arcus Biosciences (RCUS) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Zacks Investment ResearchNov 4, 2026 · 20:46 ETEARNINGS EXPECTED BY FEB 24
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Lags Revenue Estimates

Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.27 per share a year ago.…

● Business WireNov 4, 2026 · 16:05 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 24
Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of canc…

● Business WireNov 2, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 in London

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and…

● Business WireOct 26, 2026 · 16:35 ETCOMPANY'S OWN WORDS
Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of canc…

● Business WireOct 21, 2026 · 22:53 ETCOMPANY'S OWN WORDS
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immu…

● PRNewsWireOct 21, 2026 · 16:25 ET
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Arcus Biosciences, Inc. ( NYSE : RCUS) breached their fiduciary dutie…

● Business WireOct 21, 2026 · 16:22 ETCOMPANY'S OWN WORDS
Arcus Biosciences Announces Commencement of Public Offering of Common Stock

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer…

● Seeking AlphaOct 21, 2026 · 08:35 ET
Arcus Biosciences: Encouraging Casdatifan Data, But The Hard Part Still Ahead

Arcus Biosciences presented promising ARC-20 platform data for casdatifan across first-line, second-line, and late-line clear cell renal cell carcinoma settings. RCUS's casdatifan combinations showed superior or competit…

● MarketBeatOct 21, 2026 · 05:02 ET
Arcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor Day

Arcus Biosciences NYSE: RCUS presented updated clinical and translational data for casdatifan, its investigational HIF-2 alpha inhibitor, outlining development plans across first-line, second-line and later-line clear ce…

● Seeking AlphaOct 20, 2026 · 18:23 ET
Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy Transcript

Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy Transcript…

● Zacks Investment ResearchOct 20, 2026 · 11:06 ETEARNINGS EXPECTED BY FEB 24
Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

● Business WireOct 20, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of canc…

● Business WireOct 9, 2026 · 16:35 ETCOMPANY'S OWN WORDS
Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of canc…

● Business WireSep 24, 2026 · 16:35 ETCOMPANY'S OWN WORDS
Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of canc…

● Business WireSep 22, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of canc…

● Seeking AlphaSep 15, 2026 · 17:41 ET
Arcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Arcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

● Business WireSep 9, 2026 · 16:35 ET
Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer an…

● Seeking AlphaSep 9, 2026 · 14:37 ET
Arcus Biosciences, Inc. (RCUS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Arcus Biosciences, Inc. (RCUS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript…

● Business WireAug 26, 2026 · 16:05 ET
Arcus Biosciences to Participate in Three Upcoming Investor Conferences

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and infl…

● Defense WorldAug 25, 2026 · 03:52 ETEARNINGS EXPECTED BY FEB 24
BlackRock Inc. Makes New $506.11 Million Investment in Arcus Biosciences, Inc. $RCUS

BlackRock Inc. bought a new stake in Arcus Biosciences, Inc. (NYSE: RCUS) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional inves…

● PRNewsWireAug 19, 2026 · 19:58 ET
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Arcus Biosciences, Inc. ( NYSE : RCUS)  breached their fiduciary duti…

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 24. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA31−0.4%
WDAY4−5.8%
EG3−2.0%

Article counts from the last market-wide feed page, across every symbol we track and not just RCUS · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.